Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CONMED Co. stock logo
CNMD
CONMED
$72.79
+2.3%
$75.71
$61.05
$138.47
$2.24B1.37578,835 shs507,432 shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$6.70
+1.5%
$6.97
$4.14
$9.37
$2.61B1.371.21 million shs1.11 million shs
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$108.37
+1.2%
$100.55
$78.28
$203.40
$2.61B0.72219,407 shs224,061 shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shs40 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CONMED Co. stock logo
CNMD
CONMED
+2.29%+2.81%-2.40%-13.87%-39.56%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
+1.52%-10.31%-1.90%+4.85%+31.37%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
+1.19%+7.61%+10.36%+9.53%-46.01%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%+128.29%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CONMED Co. stock logo
CNMD
CONMED
4.9912 of 5 stars
3.43.02.54.33.31.74.4
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
3.498 of 5 stars
4.20.00.00.02.31.71.9
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.8762 of 5 stars
2.52.00.03.92.02.51.9
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.7299 of 5 stars
1.10.00.04.50.01.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CONMED Co. stock logo
CNMD
CONMED
2.86
Moderate Buy$107.8648.18% Upside
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
2.47
Hold$8.7831.01% Upside
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.00
Buy$123.0013.50% Upside
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
2.25
Hold$25.77-17.48% Downside

Current Analyst Ratings

Latest GDRX, CNMD, ICUI, and IMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2024
CONMED Co. stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$107.00
4/25/2024
CONMED Co. stock logo
CNMD
CONMED
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$115.00 ➝ $75.00
4/25/2024
CONMED Co. stock logo
CNMD
CONMED
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$98.00 ➝ $77.00
4/25/2024
CONMED Co. stock logo
CNMD
CONMED
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $95.00
4/25/2024
CONMED Co. stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$129.00 ➝ $107.00
4/10/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$9.00
3/25/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$7.50 ➝ $10.00
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.50
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$5.00 ➝ $8.00
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$7.00 ➝ $8.00
3/1/2024
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$6.50 ➝ $7.50
(Data available from 5/14/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CONMED Co. stock logo
CNMD
CONMED
$1.24B1.80$6.19 per share11.75$27.13 per share2.68
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$750.27M3.53$0.42 per share15.99$1.93 per share3.47
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$2.26B1.17$15.50 per share6.99$87.96 per share1.23
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CONMED Co. stock logo
CNMD
CONMED
$64.46M$2.6127.8913.210.686.53%13.78%4.86%7/24/2024 (Estimated)
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
-$8.87M-$0.01N/A21.613.62-0.86%3.45%1.70%8/14/2024 (Estimated)
ICU Medical, Inc. stock logo
ICUI
ICU Medical
-$29.66M-$2.45N/A20.14N/A-2.63%5.38%2.58%8/5/2024 (Estimated)
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A

Latest GDRX, CNMD, ICUI, and IMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2024Q1 2024
CONMED Co. stock logo
CNMD
CONMED
$0.74$0.79+$0.05$0.95$307.06 million$312.27 million      
2/29/2024Q4 2023
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.02$0.02N/A$0.10$195.59 million$196.64 million
2/27/2024Q4 2023
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$0.85$1.24+$0.39$3.19$564.77 million$587.86 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CONMED Co. stock logo
CNMD
CONMED
$0.801.10%N/A30.65%N/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
N/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
N/AN/AN/AN/AN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A

Latest GDRX, CNMD, ICUI, and IMGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2024
CONMED Co. stock logo
CNMD
CONMED
quarterly$0.201%3/14/20243/15/20244/5/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CONMED Co. stock logo
CNMD
CONMED
1.16
2.18
1.08
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
1.02
6.29
6.29
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.76
2.61
1.09
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CONMED Co. stock logo
CNMD
CONMED
N/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
63.77%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
96.10%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%

Insider Ownership

CompanyInsider Ownership
CONMED Co. stock logo
CNMD
CONMED
6.80%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
1.37%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
6.70%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CONMED Co. stock logo
CNMD
CONMED
4,00030.80 million28.71 millionOptionable
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
694395.00 million389.59 millionOptionable
ICU Medical, Inc. stock logo
ICUI
ICU Medical
14,00024.37 million22.73 millionOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable

GDRX, CNMD, ICUI, and IMGN Headlines

Recent News About These Companies

In Oncology, Antibody-Drug Conjugates Are a Hot Ticket
Polaris Global Equity Composite Q1 2024 Commentary
3 Potential Biopharma Buyout Targets
CERE Aug 2024 30.000 call
AbbVie concludes acquisition of ImmunoGen
AbbVie concludes acquisition of ImmunoGen for $10.1bn
Barclays Keeps Their Hold Rating on ImmunoGen (IMGN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

CONMED logo

CONMED

NYSE:CNMD
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
GoodRx logo

GoodRx

NASDAQ:GDRX
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
ICU Medical logo

ICU Medical

NASDAQ:ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
ImmunoGen logo

ImmunoGen

NASDAQ:IMGN
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.